Written by Sean Kimbrough, Founder & Executive Director, Courage Against Cancer
Sourced from peer-reviewed and IRB-registered clinical research · Last updated July 20, 2026
Table of Contents Introduction Glossary What Makes a Study Design Observational — and Why Does It Matter? Why Self-Reported Outcomes Are Especially Problematic in Cancer Research How These Design Limits Apply Directly to the Hulscher et al. Study Additional Related Articles FAQ Conclusion Medical Disclaimer Introduction At Courage Against Cancer (CAC), we help cancer patients and caregivers evaluate emerging research with the same rigor their oncologists apply. When a study claims that 84.4% of cancer patients experienced “clinical benefit” from an off-label drug combination, the natural impulse is hope — but the most important question isn’t what the study found. It’s how the study was designed to find it. Understanding how to evaluate cancer treatment claims and find reliable information is the foundation for evaluating viral claims responsibly. Glossary Observational Study: A research design in which investigators observe participants without controlling their treatment, making it impossible to rule out alternative explanations for outcomes. Self-Reported Outcome: Data collected based on patients’ own accounts of their experience rather than objective clinical measurement, introducing potential for recall bias and subjective interpretation. Confounding Variable: An unmeasured factor that influences measurable improvement in symptoms attributable to a patient’s belief they are receiving effective treatment, not to the treatment itself. What Makes a Study Design Observational — and Why Does It Matter? In an observational study , researchers do not randomly assign participants to treatment or control groups. Patients self-select into treatment, often because they are motivated, health-literate, or already pursuing multiple interventions simultaneously. Without randomization, there is no control group against which outcomes can be meaningfully compared. A patient who improves may have improved due to standard therapy, lifestyle changes, natural disease fluctuation, or regression to the mean — not the drug being studied. Observational designs are vulnerable to selection bias : participants may differ systematically from the broader cancer population in ways that inflate apparent benefit. This is not a minor technical limitation. It is the central reason why understanding the difference between an observational study and a randomized controlled clinical trial matters so profoundly before regulatory bodies and oncologists consistently require randomized controlled trial (RCT) data before changing clinical practice. Why Self-Reported Outcomes Are Especially Problematic in Cancer Research The Hulscher et al. study’s headline figure — an 84.4% “clinical benefit” rate — is derived from patients’ self-reports, not from independently verified tumor imaging, pathology, or validated oncology endpoints like overall survival or progression-free survival. Self-reported data in cancer studies is particularly susceptible to the placebo effect , especially when participants have paid for a product, believe strongly in its value, or are receiving significant personal attention from practitioners. Recall bias further distorts self-reported outcomes: patients who feel better are more likely to complete follow-up surveys, while those who deteriorate or die may be systematically missing from the dataset. Notably, only 122 of the original 197 patients completed the six-month follow-up — a dropout rate that alone could substantially skew results if non-completers fared worse. Rigorous cancer trials use objective, pre-specified oncology endpoints validated by independent review — a standard this study does not meet. How These Design Limits Apply Directly to the Hulscher et al. Study The study enrolled 197 patients across heterogeneous cancer types without stratification by stage, prior treatment history, or concurrent standard-of-care therapy — making it impossible to isolate the effect of ivermectin-mebendazole from other variables. The June 1, 2026 Expression of Concern published in Anticancer Research specifically flagged unresolved questions about data verifiability and statistical reliability — concerns that map directly onto these methodological weaknesses. All 12 authors hold affiliations with and/or compensation from The Wellness Company (TWC) and/or the McCullough Foundation. TWC is the sole commercial seller of the compounded ivermectin-mebendazole product evaluated — a conflict of interest that compounds the credibility concerns already embedded in the study design. This study should not be confused with the early-stage laboratory and preclinical research into ivermectin’s mechanisms explored in what the science actually says about ivermectin as a potential cancer treatment, which operates under independent scientific oversight and does not involve commercial products. One legitimately registered human oncology trial — NCT05318469, evaluating ivermectin alongside checkpoint inhibitors in metastatic triple-negative breast cancer — represents the kind of structured, oversight-governed research design this study lacks. Patients should verify its current status independently at ClinicalTrials.gov. Patients who want to understand the broader conversation around repurposed drugs in oncology can explore how researchers and clinicians distinguish between hypothesis-generating findings and evidence sufficient to guide treatment decisions. Additional Related Articles 📖 Understanding conflicts of interest in cancer drug research — Explains how financial relationships between researchers and commercial entities can influence study design, reporting, and interpretation. 📖 What the Expression of Concern on the Hulscher ivermectin study actually means — Details what journal-issued expressions of concern signal about a study’s credibility and how patients should interpret them. 📖 How to evaluate a cancer clinical trial before considering participation — Guides patients and caregivers through the key questions to ask when assessing whether a study meets rigorous safety and scientific standards. FAQ Q: Can an observational study ever provide useful information about cancer treatments? Yes — observational studies can generate hypotheses and identify patterns worth investigating. However, they cannot establish that a treatment caused an outcome. They are starting points, not endpoints, for clinical evidence. Q: Why is an 84.4% benefit rate not convincing on its own? Without a control group, we have no baseline for comparison. If 80% of similar patients improve on standard care alone, an 84.4% self-reported rate in an uncontrolled study tells us very little about the drug’s contribution. Q: Where can I find legitimately designed cancer clinical trials? ClinicalTrials.gov is the authoritative public registry for all registered U.S. clinical trials, including active oncology studies. Your oncologist can help you assess eligibility and safety for specific trials. Conclusion Study design is not a bureaucratic detail — it is the architecture that determines whether a result is meaningful or misleading. The Hulscher et al. study’s observational, self-reported framework, combined with its unresolved data integrity concerns, means its headline finding cannot support clinical decisions. Courage Against Cancer (CAC) encourages patients to bring questions about emerging research to their oncology team before acting. Medical Disclaimer This article is produced by Courage Against Cancer (CAC) for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Ivermectin and mebendazole are not approved by the FDA for cancer treatment. Cancer patients should consult their licensed oncologist or healthcare provider before making any changes to their treatment plan. Clinical trial information should be independently verified at ClinicalTrials.gov, as trial status changes over time.
About This Content: This article was written and curated by CAC’s founder, drawing on peer-reviewed and IRB-registered clinical research. CAC is in the process of establishing a formal Medical Review Board and will update our content review process as reviewers join. This content is for educational purposes only and is not medical advice — always consult your healthcare team before making treatment decisions.